Basiliximab


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Prophylaxis of acute graft rejection in renal transplantation
Adult: In combination w/ ciclosporin and corticosteroids: 20 mg by bolus inj or by infusion over 20-30 min 2 hr prior to transplantation, followed by 20 mg after 4 days, withhold 2nd dose if severe hypersensitivity or graft loss occurs.
Child: In combination w/ ciclosporin and corticosteroids: <35 kg: 10 mg by bolus inj or by infusion over 20-30 min 2 hr before surgery, repeated once 4 days later; ≥35 kg: Same as adult dose. Withhold 2nd dose if graft loss or severe hypersensitivity reaction occurs.
Hướng dẫn pha thuốc
Reconstitute 10 mg and 20 mg vial w/ 2.5 mL and 5 mL sterile water for inj, respectively. To prepare the soln for infusion, further dilute w/ 25 mL (10 mg) or 50mL (20 mg) NaCl 0.9% soln or dextrose 5% in water.
Thận trọng
Re-exposure to a subsequent course of therapy in patient who has previously received basiliximab. Childn. Pregnancy and lactation.
Phản ứng phụ
Anaphylaxis and other severe, acute hypersensitivity reactions (e.g. hypotension, tachycardia, cardiac failure, dyspnoea, wheezing, bronchospasm, pulmonary oedema, resp failure, urticaria, rash, pruritus, sneezing), lymphoproliferative disorders, opportunistic infections; constipation, nausea, diarrhoea, abdominal pain, vomiting, dyspepsia, enlarged abdomen, esophagitis, flatulence, gastroenteritis, GI hemorrhage, gum hyperplasia, melaena, moniliasis, ulcerative stomatitis; pain, peripheral oedema, fever, accidental trauma, asthenia, fatigue, malaise, rigors, sepsis; hyperkalaemia, hypokalaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia, acidosis, dehydration, DM, fluid overload, hypercalcaemia, hyperlipaemia, hypertriglyceridaemia, hypocalcaemia, hypoglycaemia, hypomagnesaemia, hypoproteinaemia, wt gain; headache, tremor, dizziness, neuropathy, paraesthesia, hypoaesthesia; UTI, albuminuria, dysuria, haematuria, oliguria, abnormal renal function, renal tubular necrosis, urinary retention, ureteral disorder; HTN; acne; insomnia; anaemia, polycythaemia; haematoma, haemorrhage, purpura, thrombocytopenia, thrombosis; arrhythmia, atrial fibrillation; arthralgia, arthropathy, back pain, bone fracture, cramps, hernia, myalgia, leg pain; impotence; cataract, conjunctivitis, abnormal vision; hypertrichosis, skin ulceration.
MonitoringParameters
Monitor signs and symptoms of acute rejection, infection and hypersensitivity; cardiorespiratory and renal function.
Tương tác
May diminish response to inactivated vaccines. May enhance the adverse/toxic effect of live vaccines, avoid concomitant admin.
Tác dụng
Description: Basiliximab is a chimeric murine/human monoclonal antibody. It blocks the α-chain (CD25 antigen) of the interleukin-2 receptor complex on the surface of activated T-lymphocytes.
Duration: 36 days ± 14 days.
Pharmacokinetics:
Distribution: Volume of distribution: 8.6 ± 4.1 L.
Excretion: Terminal half-life: 7 days.
Bảo quản
Store between 2-8°C. Reconstituted soln: 2-8°C for 24 hr or 4 hr at room temp.
Phân loại MIMS
Phân loại ATC
L04AC02 - basiliximab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
References
Anon. Basiliximab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/08/2016.

Buckingham R (ed). Basiliximab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/08/2016.

Joint Formulary Committee. Basiliximab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Basiliximab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/08/2016.

Simulect inj, powder, for solution (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/08/2016.

Wickersham RM. Basiliximab. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. https://www.wolterskluwercdi.com/facts-comparisons-online/. Accessed 30/08/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Basiliximab từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Simulect
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in